Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
6 "α-synuclein"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Review Articles
Article image
α-Synuclein: A Promising Biomarker for Parkinson’s Disease and Related Disorders
Taku Hatano, Ayami Okuzumi, Gen Matsumoto, Taiji Tsunemi, Nobutaka Hattori
J Mov Disord. 2024;17(2):127-137.   Published online April 9, 2024
DOI: https://doi.org/10.14802/jmd.24075
  • 3,832 View
  • 394 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDF
Mutations in the SNCA gene, which encodes α-synuclein (α-syn), play a key role in the development of genetic Parkinson’s disease (PD). α-Syn is a major component of Lewy bodies in PD and glial cytoplasmic inclusions in multiple system atrophy (MSA). Rapid eye movement sleep behavior disorder patients often progress to PD, dementia with Lewy bodies, or MSA, which are collectively known as α-synucleinopathies. The loss of dopaminergic neurons with Lewy bodies precedes motor dysfunction in these diseases, but the mechanisms of neurodegeneration due to α-syn aggregation are poorly understood. Monitoring α-syn aggregation in vivo could serve as a diagnostic biomarker and help elucidate pathogenesis, necessitating a simple and accurate detection method. Seed amplification assays (SAAs), such as real-time quaking-induced conversion and protein misfolding cyclic amplification, are used to detect small amounts of abnormally structured α-syn protofibrils, which are central to aggregation. These methods are promising for the early diagnosis of α-synucleinopathy. Differences in α-syn filament structures between α-synucleinopathies, as observed through transmission electron microscopy and cryo-electron microscopy, suggest their role in the pathogenesis of neurodegeneration. SAAs may differentiate between subtypes of α-synucleinopathy and other diseases. Efforts are also being made to identify α-syn from blood using various methods. This review introduces body fluid α-syn biomarkers based on pathogenic α-syn seeds, which are expected to redefine α-synucleinopathy diagnosis and staging, improving clinical research accuracy and facilitating biomarker development.

Citations

Citations to this article as recorded by  
  • Selective detection of alpha synuclein amyloid fibrils by faradaic and non-faradaic electrochemical impedance spectroscopic approaches
    Hussaini Adam, Subash C.B. Gopinath, Hemavathi Krishnan, Tijjani Adam, Makram A. Fakhri, Evan T. Salim, A. Shamsher, Sreeramanan Subramaniam, Yeng Chen
    Bioelectrochemistry.2025; 161: 108800.     CrossRef
  • Hypoxia Pathways in Parkinson’s Disease: From Pathogenesis to Therapeutic Targets
    Yuanyuan Gao, Jiarui Zhang, Tuoxian Tang, Zhenjiang Liu
    International Journal of Molecular Sciences.2024; 25(19): 10484.     CrossRef
  • Circadian rhythm disruption: a potential trigger in Parkinson’s disease pathogenesis
    Ke Xu, Yu Zhang, Yue Shi, Yake Zhang, Chengguang Zhang, Tianjiao Wang, Peizhu Lv, Yan Bai, Shun Wang
    Frontiers in Cellular Neuroscience.2024;[Epub]     CrossRef
Article image
Ultrastructures of α-Synuclein Filaments in Synucleinopathy Brains and Experimental Models
Airi Tarutani, Masato Hasegawa
J Mov Disord. 2024;17(1):15-29.   Published online November 22, 2023
DOI: https://doi.org/10.14802/jmd.23213
  • 2,817 View
  • 471 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDF
Intracellular α-synuclein (α-syn) inclusions are a neuropathological hallmark of Lewy body disease (LBD) and multiple system atrophy (MSA), both of which are termed synucleinopathies. LBD is defined by Lewy bodies and Lewy neurites in neurons, while MSA displays glial cytoplasmic inclusions in oligodendrocytes. Pathological α-syn adopts an ordered filamentous structure with a 5–10 nm filament diameter, and this conformational change has been suggested to be involved in the disease onset and progression. Synucleinopathies also exhibit characteristic ultrastructural and biochemical properties of α-syn filaments, and α-syn strains with distinct conformations have been identified. Numerous experimental studies have supported the idea that pathological α-syn self-amplifies and spreads throughout the brain, during which processes the conformation of α-syn filaments may drive the disease specificity. In this review, we summarize the ultrastructural features and heterogeneity of α-syn filaments in the brains of patients with synucleinopathy and in experimental models of seeded α-syn aggregation.

Citations

Citations to this article as recorded by  
  • α-Synuclein: A Promising Biomarker for Parkinson’s Disease and Related Disorders
    Taku Hatano, Ayami Okuzumi, Gen Matsumoto, Taiji Tsunemi, Nobutaka Hattori
    Journal of Movement Disorders.2024; 17(2): 127.     CrossRef
  • Exploring the Potential of Biomimetic Peptides in Targeting Fibrillar and Filamentous Alpha-Synuclein—An In Silico and Experimental Approach to Parkinson’s Disease
    Sophia A. Frantzeskos, Mary A. Biggs, Ipsita A. Banerjee
    Biomimetics.2024; 9(11): 705.     CrossRef
Article image
Multiple System Atrophy: Advances in Diagnosis and Therapy
Hirohisa Watanabe, Sayuri Shima, Yasuaki Mizutani, Akihiro Ueda, Mizuki Ito
J Mov Disord. 2023;16(1):13-21.   Published online December 20, 2022
DOI: https://doi.org/10.14802/jmd.22082
  • 6,820 View
  • 527 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDF
This review summarizes improvements in understanding the pathophysiology and early clinical symptoms of multiple system atrophy (MSA) and advancements in diagnostic methods and disease-modifying therapies for the condition. In 2022, the Movement Disorder Society proposed new diagnostic criteria to develop disease-modifying therapies and promote clinical trials of MSA since the second consensus was proposed in 2008. Regarding pathogenesis, cutting-edge findings have accumulated on the interactions of α-synuclein, neuroinflammation, and oligodendroglia with neurons. In neuroimaging, introducing artificial intelligence, machine learning, and deep learning has notably improved diagnostic accuracy and individual analyses. Advancements in treatment have also been achieved, including immunotherapy therapy against α-synuclein and serotonin-targeted and mesenchymal stem cell therapies, which are thought to affect several aspects of the disease, including neuroinflammation. The accelerated progress in clarifying the pathogenesis of MSA over the past few years and the development of diagnostic techniques for detecting early-stage MSA are expected to facilitate the development of disease-modifying therapies for one of the most intractable neurodegenerative diseases.

Citations

Citations to this article as recorded by  
  • A Blinded Evaluation of Brain Morphometry for Differential Diagnosis of Atypical Parkinsonism
    Kazuya Kawabata, Florian Krismer, Beatrice Heim, Anna Hussl, Christoph Mueller, Christoph Scherfler, Elke R. Gizewski, Klaus Seppi, Werner Poewe
    Movement Disorders Clinical Practice.2024; 11(4): 381.     CrossRef
  • The potential of phosphorylated α‐synuclein as a biomarker for the diagnosis and monitoring of multiple system atrophy
    Toufik Abdul‐Rahman, Ranferi Eduardo Herrera‐Calderón, Arjun Ahluwalia, Andrew Awuah Wireko, Tomas Ferreira, Joecelyn Kirani Tan, Maximillian Wolfson, Shankhaneel Ghosh, Viktoriia Horbas, Vandana Garg, Asma Perveen, Marios Papadakis, Ghulam Md Ashraf, Ath
    CNS Neuroscience & Therapeutics.2024;[Epub]     CrossRef
  • Delivering the diagnosis of multiple system atrophy: a multicenter survey on Japanese neurologists’ perspectives
    Miki Yoshitake, Atsuhiko Sugiyama, Takayoshi Shimohata, Nobuyuki Araki, Masahide Suzuki, Kazumoto Shibuya, Kengo Nagashima, Nobutaka Hattori, Satoshi Kuwabara
    BMC Neurology.2024;[Epub]     CrossRef
  • Clinical comparison of the 2008 and 2022 diagnostic criteria for early multiple system atrophy-cerebellar type
    Seoyeon Kim, Kyung Ah Woo, Jung Hwan Shin, Han-Joon Kim, Beomseok Jeon
    Clinical Autonomic Research.2024; 34(6): 609.     CrossRef
  • Ocular Vestibular-Evoked Myogenic Potential Assists in the Differentiation of Multiple System Atrophy From Parkinson’s Disease
    Keun-Tae Kim, Kyoungwon Baik, Sun-Uk Lee, Euyhyun Park, Chan-Nyoung Lee, Tonghoon Woo, Yukang Kim, Seoui Kwag, Hyunsoh Park, Ji-Soo Kim
    Journal of Movement Disorders.2024; 17(4): 398.     CrossRef
Article image
Diagnostic Criteria for Dementia with Lewy Bodies: Updates and Future Directions
Masahito Yamada, Junji Komatsu, Keiko Nakamura, Kenji Sakai, Miharu Samuraki-Yokohama, Kenichi Nakajima, Mitsuhiro Yoshita
J Mov Disord. 2020;13(1):1-10.   Published online November 8, 2019
DOI: https://doi.org/10.14802/jmd.19052
  • 28,407 View
  • 1,758 Download
  • 55 Web of Science
  • 61 Crossref
AbstractAbstract PDF
The aim of this article is to describe the 2017 revised consensus criteria for the clinical diagnosis of dementia with Lewy bodies (DLB) with future directions for the diagnostic criteria. The criteria for the clinical diagnosis of probable and possible DLB were first published as the first consensus report in 1996 and were revised in the third consensus report in 2005. After discussion at the International DLB Conference in Fort Lauderdale, Florida, USA, in 2015, the International DLB Consortium published the fourth consensus report including the revised consensus criteria in 2017. The 2017 revised criteria clearly distinguish between clinical features and diagnostic biomarkers. Significant new information about previously reported aspects of DLB has been incorporated, with increased diagnostic weighting given to rapid eye movement (REM) sleep behavior disorder (RBD) and iodine-123-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. Future directions include the development of the criteria for early diagnosis (prodromal DLB) and the establishment of new biomarkers that directly indicate Lewy-related pathology, including α-synuclein imaging, biopsies of peripheral tissues (skin, etc.) for the demonstration of α-synuclein deposition, and biochemical markers (cerebrospinal fluid/blood), as well as the pathological evaluation of the sensitivity and specificity of the 2017 revised diagnostic criteria. In conclusion, the revised consensus criteria for the clinical diagnosis of DLB were reported with the incorporation of new information about DLB in 2017. Future directions include the development of the criteria for early diagnosis and the establishment of biomarkers directly indicative of Lewy-related pathology.

Citations

Citations to this article as recorded by  
  • The Role of Electroconvulsive Therapy in the Treatment of Catatonia Associated With Lewy Body Dementia: A Case Report
    Javeria Sahib Din, Thomas Boes, Ernesto Navarro Garcia, Hiba Al-Rubaye
    Cureus.2024;[Epub]     CrossRef
  • α-Synuclein pathology from the body to the brain: so many seeds so close to the central soil
    Yunying Yang, Zhentao Zhang
    Neural Regeneration Research.2024; 19(7): 1463.     CrossRef
  • Suspecting Non-Alzheimer’s Pathologies and Mixed Pathologies: A Comparative Study Between Brain Metabolism and Tau Images
    Vincent Malotaux, Lise Colmant, Lisa Quenon, Lara Huyghe, Thomas Gérard, Laurence Dricot, Adrian Ivanoiu, Renaud Lhommel, Bernard Hanseeuw
    Journal of Alzheimer's Disease.2024; 97(1): 421.     CrossRef
  • Supercomplex formation of mitochondrial respiratory chain complexes in leukocytes from patients with neurodegenerative diseases
    Tsukasa Hara, Ryosuke Amagai, Ryuji Sakakibara, Ayako Okado-Matsumoto
    The Journal of Biochemistry.2024; 175(3): 289.     CrossRef
  • Latest advances in mechanisms of epileptic activity in Alzheimer’s disease and dementia with Lewy Bodies
    Mariane Vicente, Kwaku Addo-Osafo, Keith Vossel
    Frontiers in Neurology.2024;[Epub]     CrossRef
  • The clinical diagnosis of Parkinson's disease
    Renato P. Munhoz, Vitor Tumas, José Luiz Pedroso, Laura Silveira-Moriyama
    Arquivos de Neuro-Psiquiatria.2024; 82(06): 001.     CrossRef
  • Identification of Potentially Repurposable Drugs for Lewy Body Dementia Using a Network-Based Approach
    Megha Manoj, Siddarth Sowmyanarayan, Arjun V. Kowshik, Jhinuk Chatterjee
    Journal of Molecular Neuroscience.2024;[Epub]     CrossRef
  • Altered structural and functional connectivity in Posterior Cortical Atrophy and Dementia with Lewy bodies
    Neha Atulkumar Singh, Austin W. Goodrich, Jonathan Graff-Radford, Mary M. Machulda, Irene Sintini, Arenn F. Carlos, Carling G. Robinson, Robert I. Reid, Val J. Lowe, Clifford R. Jack, Ronald C. Petersen, Bradley F. Boeve, Keith A. Josephs, Kejal Kantarci,
    NeuroImage.2024; 290: 120564.     CrossRef
  • Clinicopathological correlation of cerebrospinal fluid alpha‐synuclein seed amplification assay in a behavioral neurology autopsy cohort
    Niyatee Samudra, D. Luke Fischer, Steven Lenio, Argentina Lario Lago, Peter A. Ljubenkov, Julio C. Rojas, William W. Seeley, Salvatore Spina, Adam M. Staffaroni, Jonathan Tablante, Fattin Wekselman, Jennifer Lamoureux, Luis Concha‐Marambio, Lea T. Grinber
    Alzheimer's & Dementia.2024; 20(5): 3334.     CrossRef
  • New insight of exercise on dementia; combinatory effects of physical and cognitive exercise
    Hyo-Jeong Cha, Jun Hong Park, Changwan Hong
    Molecular & Cellular Toxicology.2024; 20(4): 767.     CrossRef
  • Diagnostic Challenge of an Advanced Stage Dementia Case
    Emin Taşkıran
    European Journal of Geriatrics and Gerontology.2024; 6(1): 73.     CrossRef
  • Dementia with Lewy bodies
    Cheri M. Jrolf
    JAAPA.2024;[Epub]     CrossRef
  • Absolute quantitation of sympathetic nerve activity using [123I] metaiodobenzylguanidine SPECT-CT in neurology
    Shintaro Saito, Kenichi Nakajima, Junji Komatsu, Takayuki Shibutani, Hiroshi Wakabayashi, Hiroshi Mori, Aki Takata, Kenjiro Ono, Seigo Kinuya
    EJNMMI Reports.2024;[Epub]     CrossRef
  • Sympathetic 123I-metaiodobenzylguanidine index for Lewy body disease: probability-based diagnosis and identifying patients exempt from late imaging
    Kenichi Nakajima, Takeshi Matsumura, Junji Komatsu, Hiroshi Wakabayashi, Kenjiro Ono, Seigo Kinuya
    Annals of Nuclear Medicine.2024; 38(10): 814.     CrossRef
  • The usefulness of combined analysis using CIScore and VSRAD parameters for differentiating between dementia with Lewy body and Alzheimer’s disease
    Gaku Honda, Shigeki Nagamachi, Mai Takahashi, Yukie Higuma, Tomonobu Tani, Kosuke Hida, Kengo Yoshimitsu, Koji Ogomori, Yoshio Tsuboi
    Japanese Journal of Radiology.2024; 42(10): 1206.     CrossRef
  • Biofluid Detection of Pathological α-Synuclein in the Prodromal Phase of Synucleinopathies
    Annika Kluge, Alex Iranzo, Daniela Berg, Bastiaan R. Bloem, Lorraine V. Kalia, Ron B. Postuma
    Journal of Parkinson's Disease.2024; 14(s2): S323.     CrossRef
  • Multiple system atrophy: Diagnostic challenges and a proposed diagnostic algorithm
    Deepmala Nandanwar, Daniel D. Truong
    Clinical Parkinsonism & Related Disorders.2024; 11: 100271.     CrossRef
  • Substantia nigra hyperechogenicity and brain ventricular size as biomarkers of early dementia with Lewy bodies
    Anna Planas-Ballvé, Jose Rios, Mireia Gea, Neus Rabaneda-Lombarte, Lourdes Ispierto, Laia Grau, Marta Jiménez, Cynthia Cáceres, Sílvia Martínez, Katrin Beyer, Ramiro Álvarez, Pau Pastor, Dolores Vilas
    Alzheimer's Research & Therapy.2024;[Epub]     CrossRef
  • The Diagnostic Challenges of Late-onset Neuropsychiatric Symptoms and Early-onset Dementia: A Clinical and Neuropathological Case Study
    Miguel Restrepo-Martinez, Ramiro Ruiz-Garcia, Jacob Houpt, Lee Cyn Ang, Sumit Chaudhari, Elizabeth Finger
    Cognitive and Behavioral Neurology.2024; 37(4): 226.     CrossRef
  • Quantitative proteomic analysis using a mouse model of Lewy body dementia induced by α-synuclein preformed fibrils injection
    Fatih Akkentli, In kyu Jang, Yoonseop Choi, Young Min, Jinhee Park, Heejin Jo, Leoni Kim, Aashi Mendpara, Bikram Bains, Dongyoon Yoo, Jinchong Xu, Chan Hyun Na, Sung-Ung Kang
    Frontiers in Dementia.2024;[Epub]     CrossRef
  • Cognitive impairment in Parkinson’s disease and other parkinsonian syndromes
    Alexandros Giannakis, Chrissa Sioka, Eugenia Kloufetou, Spiridon Konitsiotis
    Journal of Neural Transmission.2024;[Epub]     CrossRef
  • Magnetic resonance imaging in the diagnosis of progressive supranuclear palsy: A case report and review of literature
    Baraka Alphonce, Francisca Komanya, Mbelwa Bitesigilwe, John R. Meda, Azan Nyundo
    Clinical Case Reports.2023;[Epub]     CrossRef
  • Parkinson's disease fluid biomarkers for differential diagnosis of atypical parkinsonian syndromes
    Jun Yang, Ayotimofe Idowu, Liana Rosenthal, Xiaobo Mao
    Clinical and Translational Discovery.2023;[Epub]     CrossRef
  • Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinson’s disease dementia
    Irene Frigerio, Max A. Laansma, Chen-Pei Lin, Emma J. M. Hermans, Maud M. A. Bouwman, John G. J. M. Bol, Yvon Galis-de Graaf, Dagmar H. Hepp, Annemieke J. M. Rozemuller, Frederik Barkhof, Wilma D. J. van de Berg, Laura E. Jonkman
    Translational Neurodegeneration.2023;[Epub]     CrossRef
  • Machine learning-based prediction of conversion coefficients for I-123 metaiodobenzylguanidine heart-to-mediastinum ratio
    Koichi Okuda, Kenichi Nakajima, Chiemi Kitamura, Michael Ljungberg, Tetsuo Hosoya, Yumiko Kirihara, Mitsumasa Hashimoto
    Journal of Nuclear Cardiology.2023; 30(4): 1630.     CrossRef
  • Costs During the Last Five Years of Life for Patients with Clinical and Pathological Confirmed Diagnosis of Lewy Body Dementia and Alzheimer’s Disease
    Carolyn W. Zhu, Yian Gu, Anton J. Kociolek, Kayri K. Fernandez, Stephanie Cosentino, Yaakov Stern
    Journal of Alzheimer's Disease.2023; 92(2): 457.     CrossRef
  • Early- and late-onset of isolated rapid eye movement sleep behavior disorder: A retrospective cohort study
    Li Zhou, Bei Huang, Jing Wang, Steven WH. Chau, Joey WY. Chan, Jihui Zhang, Mandy WM. Yu, Jessie CC. Tsang, Shirley Xin Li, Vincent CT. Mok, Yun Kwok Wing, Yaping Liu
    Sleep Medicine.2023;[Epub]     CrossRef
  • Parkinson Disease Dementia Management: an Update of Current Evidence and Future Directions
    Oliver Phillips, Debolina Ghosh, Hubert H. Fernandez
    Current Treatment Options in Neurology.2023; 25(5): 93.     CrossRef
  • Rapidly progressive dementia with severe insomnia: an unusual case of progressive supranuclear palsy mimicking dementia with Lewy bodies
    Rae On Kim, Eun Ji Lee, Seong-Ik Kim, Sung-Hye Park, Kyum-Yil Kwon
    Neurological Sciences.2023; 44(8): 2953.     CrossRef
  • Significance of clinical symptoms and red flags in early differential diagnosis of Parkinson’s disease and atypical Parkinsonian syndromes
    Nils Schröter, Thilo van Eimeren, Joseph Classen, Johannes Levin, Christoph Redecker, Martin Wolz, Lars Tönges
    Journal of Neural Transmission.2023; 130(6): 839.     CrossRef
  • Electroencephalography in young onset dementia
    Casey W Brown, Huei-Yang Chen, Peter K Panegyres
    BMC Neurology.2023;[Epub]     CrossRef
  • Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers
    Lucy L. Gibson, Carla Abdelnour, Joyce Chong, Clive Ballard, Dag Aarsland
    Current Opinion in Neurology.2023;[Epub]     CrossRef
  • Coexistence of Posterior Cortical Atrophy and Parkinson’s Disease
    Eun-Byul Ko, Il-Joong Hwang, Jung-Woo Kim, Dar-Eun Jung, Ju-Suk Lee, Sang-Won Yoo, Joong-Seok Kim
    Journal of the Korean Neurological Association.2023; 41(3): 216.     CrossRef
  • Toward a new nosology of neurodegenerative diseases
    Manuel Menéndez‐González
    Alzheimer's & Dementia.2023; 19(8): 3731.     CrossRef
  • Autonomic dysfunction in dementia with Lewy bodies: Focusing on cardiovascular and respiratory dysfunction
    Katsuyoshi Mizukami
    Psychiatry and Clinical Neurosciences Reports.2023;[Epub]     CrossRef
  • Beyond Strains: Molecular Diversity in Alpha-Synuclein at the Center of Disease Heterogeneity
    Marcelina J. Wojewska, Maria Otero-Jimenez, Jose Guijarro-Nuez, Javier Alegre-Abarrategui
    International Journal of Molecular Sciences.2023; 24(17): 13199.     CrossRef
  • Case Study 6: The Diagnostic Challenge of a 75-Year-Old Man Who Had, Then Didn’t Have, Then Did Have Alzheimer’s Disease
    Sergio A. Ramírez-Salazar, Cassie MacRae, Mel B. Feany, Michael Miller, Hyun-Sik Yang, Mary-Ellen Meadows, Scott M. McGinnis, David Silbersweig, Seth A. Gale, Kirk R. Daffner
    The Journal of Neuropsychiatry and Clinical Neurosciences.2023; 35(4): 325.     CrossRef
  • Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson’s Disease: A Comprehensive Review
    Jamir Pitton Rissardo, Ana Letícia Fornari Caprara
    Brain Sciences.2023; 13(10): 1471.     CrossRef
  • A Unique Perspective on Lead Compounds for Dementia with the Lewy Body
    Menaka Subramani, Amuthalakshmi Sivaperuman, Ramalakshmi Natarajan, Keerthana Dhinakaran
    Medicinal Chemistry.2023; 19(10): 946.     CrossRef
  • Three-Dimensional Heart Segmentation and Absolute Quantitation of Cardiac 123I-metaiodobenzylguanidine Sympathetic Imaging Using SPECT/CT
    Shintaro Saito, Kenichi Nakajima, Takayuki Shibutani, Hiroshi Wakabayashi, Hiroto Yoneyama, Takahiro Konishi, Hiroshi Mori, Aki Takata, Seigo Kinuya
    Annals of Nuclear Cardiology.2023; 9(1): 61.     CrossRef
  • Comparison of Taiwanese and European Calibration Factors for Heart-to-Mediastinum Ratio in Multicenter 123I-mIBG Phantom Studies
    Koichi Okuda, Kenichi Nakajima, Guang-Uei Hung, Hao-Ting Wu, Derk O. Verschure, Hein J. Verberne, Chiemi Kitamura
    Annals of Nuclear Cardiology.2023; 9(1): 54.     CrossRef
  • Clinical biomarkers for Lewy body diseases
    Mai M. Abdelmoaty, Eugene Lu, Rana Kadry, Emma G. Foster, Shaurav Bhattarai, R. Lee Mosley, Howard E. Gendelman
    Cell & Bioscience.2023;[Epub]     CrossRef
  • Proteomic comparison between non‐purified cerebrospinal fluid and cerebrospinal fluid‐derived extracellular vesicles from patients with Alzheimer's, Parkinson's and Lewy body dementia
    Yael Hirschberg, Natalia Valle‐Tamayo, Oriol Dols‐Icardo, Sebastiaan Engelborghs, Bart Buelens, Roosmarijn E. Vandenbroucke, Yannick Vermeiren, Kurt Boonen, Inge Mertens
    Journal of Extracellular Vesicles.2023;[Epub]     CrossRef
  • The connection between cerebral amyloid angiopathy and Alzheimer’s disease
    Hans Rolf Jäger
    European Radiology.2023; 34(4): 2171.     CrossRef
  • Young-onset dementia with Lewy Bodies presenting with apathy and alexithymia
    Stefania Kaninia, Rosaleen A. McCarthy, Zia Saad, George P Pengas
    Neurocase.2023; 29(6): 191.     CrossRef
  • Autonomic symptoms are predictive of dementia with Lewy bodies
    Wenzheng Hu, Shuai Liu, Fei Wang, Han Zhu, Xiaoshan Du, Lingyun Ma, Jinghuan Gan, Hao Wu, Xiaodan Wang, Yong Ji
    Parkinsonism & Related Disorders.2022; 95: 1.     CrossRef
  • Delusion and Delirium in Neurodegenerative Disorders: An Overlooked Relationship?
    Daniele Urso, Valentina Gnoni, Marco Filardi, Giancarlo Logroscino
    Frontiers in Psychiatry.2022;[Epub]     CrossRef
  • Clinical Trajectories at the End of Life in Autopsy-Confirmed Dementia Patients With Alzheimer Disease and Lewy Bodies Pathologies
    Yian Gu, Anton Kociolek, Kayri K. Fernandez, Stephanie A. Cosentino, Carolyn Wei Zhu, Zhezhen Jin, James B. Leverenz, Yaakov B. Stern
    Neurology.2022;[Epub]     CrossRef
  • Diagnostic Performance for Differential Diagnosis of Atypical Parkinsonian Syndromes from Parkinson’s Disease Using Quantitative Indices of 18F-FP-CIT PET/CT
    Miju Cheon, Seung Min Kim, Sang-Won Ha, Min Ju Kang, Hea-Eun Yang, Jang Yoo
    Diagnostics.2022; 12(6): 1402.     CrossRef
  • The promise of amplification assays for accurate early detection of α-synucleinopathies: A review
    Regina Kurapova, Leonidas Chouliaras, John T. O'Brien
    Experimental Gerontology.2022; 165: 111842.     CrossRef
  • Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder
    Annette Janzen, David Vadasz, Jan Booij, Markus Luster, Damiano Librizzi, Martin T. Henrich, Lars Timmermann, Mahboubeh Habibi, Elisabeth Sittig, Geert Mayer, Fanni Geibl, Wolfgang Oertel
    Journal of Parkinson's Disease.2022; 12(6): 1921.     CrossRef
  • Lewy body Dementia: What are the challenges of early and accurate diagnosis?
    Madelaine B. Rañola
    Australasian Journal of Neuroscience.2022; 32(1): 40.     CrossRef
  • A Systematic Review and Comparison of Neurocognitive Features of Late-Life Attention-Deficit/Hyperactivity Disorder and Dementia With Lewy Bodies
    Jennifer L. Prentice, Morgan J. Schaeffer, Alexandra K. Wall, Brandy L. Callahan
    Journal of Geriatric Psychiatry and Neurology.2021; 34(5): 466.     CrossRef
  • Dementia with Lewy bodies in first-generation immigrants in a European memory clinic
    Kurt Segers, Florence Benoit, Jean-Marie Meyts, Gérald Glibert, Sophie Levy, Murielle Surquin
    Acta Neurologica Belgica.2021; 121(1): 219.     CrossRef
  • The development of new method to differentiate between Dementia with Lewy bodies and Alzheimer’s disease by cerebral perfusion SPECT-comparison to CIScore
    Gaku Honda, Shigeki Nagamachi, Masanari Nonokuma, Koichi Takano, Yasuo Kuwabara, Kengo Yoshimitsu, Hitoshi Iida, Koji Ogomori, Hiroaki Kawasaki, Yoshio Tsuboi
    Japanese Journal of Radiology.2021; 39(2): 198.     CrossRef
  • Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson’s disease
    Xue-Bing Ding, Xin-Xin Wang, Dan-Hao Xia, Han Liu, Hai-Yan Tian, Yu Fu, Yong-Kang Chen, Chi Qin, Jiu-Qi Wang, Zhi Xiang, Zhong-Xian Zhang, Qin-Chen Cao, Wei Wang, Jia-Yi Li, Erxi Wu, Bei-Sha Tang, Ming-Ming Ma, Jun-Fang Teng, Xue-Jing Wang
    Nature Medicine.2021; 27(3): 411.     CrossRef
  • Mechanisms of Neurodegeneration in Various Forms of Parkinsonism—Similarities and Differences
    Dariusz Koziorowski, Monika Figura, Łukasz M. Milanowski, Stanisław Szlufik, Piotr Alster, Natalia Madetko, Andrzej Friedman
    Cells.2021; 10(3): 656.     CrossRef
  • Advances in computerized MRI‐based biomarkers in Alzheimer’s disease
    Raymond Wong, Yishan Luo, Vincent Chung-tong Mok, Lin Shi
    Brain Science Advances.2021; 7(1): 26.     CrossRef
  • Convolutional neural network-based automatic heart segmentation and quantitation in 123I-metaiodobenzylguanidine SPECT imaging
    Shintaro Saito, Kenichi Nakajima, Lars Edenbrandt, Olof Enqvist, Johannes Ulén, Seigo Kinuya
    EJNMMI Research.2021;[Epub]     CrossRef
  • A direct comparison of the 2005 and 2017 criteria for dementia with Lewy bodies
    Kurt Segers, Florence Benoit, Jean‐Marie Meyts, Gerald Glibert, Murielle Surquin
    Psychogeriatrics.2020; 20(5): 785.     CrossRef
  • Calibrated scintigraphic imaging procedures improve quantitative assessment of the cardiac sympathetic nerve activity
    Koichi Okuda, Kenichi Nakajima, Chiemi Kitamura, Yumiko Kirihara, Mitsumasa Hashimoto, Seigo Kinuya
    Scientific Reports.2020;[Epub]     CrossRef
Article image
Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson’s Disease
Ju-Hee Kang
J Mov Disord. 2016;9(2):89-96.   Published online May 25, 2016
DOI: https://doi.org/10.14802/jmd.16017
  • 21,063 View
  • 250 Download
  • 18 Web of Science
  • 18 Crossref
AbstractAbstract PDF
Parkinson’s disease (PD) is a neurodegenerative disease with heterogeneous pathological and clinical features. Cognitive dysfunction, a frequent non-motor complication, is a risk factor for poor prognosis and shows inter-individual variation in its progression. Of the clinical studies performed to identify biomarkers of PD progression, the Parkinson’s Progression Markers Initiative (PPMI) study is the largest study that enrolled drug-naïve and very early stage PD patients. The baseline characteristics of the PPMI cohort were recently published. The diagnostic utility of cerebrospinal fluid (CSF) biomarkers, including alpha-synuclein (α-syn), total tau, phosphorylated tau at Thr181, and amyloid β1-42, was not satisfactory. However, the baseline data on CSF biomarkers in the PPMI study suggested that the measurement of the CSF biomarkers enables the prediction of future cognitive decline in PD patients, which was consistent with previous studies. To prove the hypothesis that the interaction between Alzheimer’s pathology and α-syn pathology is important to the progression of cognitive dysfunction in PD, longitudinal observational studies must be followed. In this review, the neuropathological nature of heterogeneous cognitive decline in PD is briefly discussed, followed by a summarized interpretation of baseline CSF biomarkers derived from the data in the PPMI study. The combination of clinical, biochemical, genetic and imaging biomarkers of PD constitutes a feasible strategy to predict the heterogeneous progression of PD.

Citations

Citations to this article as recorded by  
  • Highly sensitive biosensor based on IGZO thin-film transistors for detection of Parkinson's disease
    Tongzheng Li, Tongying Xu, Zhengyang Yao, Yanan Ding, Guoxia Liu, Fukai Shan
    Applied Physics Letters.2023;[Epub]     CrossRef
  • Extracellular vesicle biomarkers for cognitive impairment in Parkinson’s disease
    Joseph Blommer, Toni Pitcher, Maja Mustapic, Erden Eren, Pamela J Yao, Michael P Vreones, Krishna A Pucha, John Dalrymple-Alford, Reza Shoorangiz, Wassilios G Meissner, Tim Anderson, Dimitrios Kapogiannis
    Brain.2023; 146(1): 195.     CrossRef
  • Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders
    John P. Seibyl
    Journal of Nuclear Medicine.2023; 64(1): 12.     CrossRef
  • REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson’s disease: a cross-sectional and longitudinal study
    Fardin Nabizadeh, Kasra Pirahesh, Parya Valizadeh
    Journal of Neurology.2022; 269(9): 4836.     CrossRef
  • Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease
    Thomas Kremer, Kirsten I. Taylor, Juliane Siebourg‐Polster, Thomas Gerken, Andreas Staempfli, Christian Czech, Juergen Dukart, Douglas Galasko, Tatiana Foroud, Lana M. Chahine, Christopher S. Coffey, Tanya Simuni, Daniel Weintraub, John Seibyl, Kathleen L
    Movement Disorders.2021; 36(8): 1972.     CrossRef
  • Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis
    J. M. Hatcher-Martin, J. L. McKay, A. F. Pybus, B. Sommerfeld, J. C. Howell, F. C. Goldstein, L. Wood, W. T. Hu, S. A. Factor
    npj Parkinson's Disease.2021;[Epub]     CrossRef
  • Melatonin affects the release of exosomes and tau-content in in vitro amyloid-beta toxicity model
    Mehmet Ozansoy, Muzaffer Beyza Ozansoy, Burak Yulug, Seyda Cankaya, Ertugrul Kilic, Sule Goktekin, Ulkan Kilic
    Journal of Clinical Neuroscience.2020; 73: 237.     CrossRef
  • Disentangling the Amyloid Pathways: A Mechanistic Approach to Etiology
    Maja Malmberg, Tarja Malm, Oskar Gustafsson, Andrea Sturchio, Caroline Graff, Alberto J. Espay, Anthony P. Wright, Samir El Andaloussi, Anders Lindén, Kariem Ezzat
    Frontiers in Neuroscience.2020;[Epub]     CrossRef
  • Why would Parkinson’s disease lead to sudden changes in creativity, motivation, or style with visual art?: A review of case evidence and new neurobiological, contextual, and genetic hypotheses
    Jon O. Lauring, Tomohiro Ishizu, Hana H. Kutlikova, Felix Dörflinger, Steven Haugbøl, Helmut Leder, Ron Kupers, Matthew Pelowski
    Neuroscience & Biobehavioral Reviews.2019; 100: 129.     CrossRef
  • Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease
    Tracy R. Melzer, Megan R. Stark, Ross J. Keenan, Daniel J. Myall, Michael R. MacAskill, Toni L. Pitcher, Leslie Livingston, Sophie Grenfell, Kyla-Louise Horne, Bob N. Young, Maddie J. Pascoe, Mustafa M. Almuqbel, Jian Wang, Steven H. Marsh, David H. Mille
    Frontiers in Neurology.2019;[Epub]     CrossRef
  • Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
    Kurt A. Jellinger
    Journal of Neural Transmission.2018; 125(4): 615.     CrossRef
  • Identification of a prospective early motor progression cluster of Parkinson's disease: Data from the PPMI study
    George D. Vavougios, Triantafyllos Doskas, Constantinos Kormas, Karen A. Krogfelt, Sotirios G. Zarogiannis, Leonidas Stefanis
    Journal of the Neurological Sciences.2018; 387: 103.     CrossRef
  • Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease
    Nooshin Abbasi, Bahram Mohajer, Sima Abbasi, Payam Hasanabadi, Amirhussein Abdolalizadeh, Reza Rajimehr
    Movement Disorders.2018; 33(3): 431.     CrossRef
  • Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease
    Mahsa Dolatshahi, Shayan Pourmirbabaei, Aida Kamalian, Amir Ashraf-Ganjouei, Mehdi Yaseri, Mohammad H. Aarabi
    Frontiers in Neurology.2018;[Epub]     CrossRef
  • Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study
    Manuel Delgado‐Alvarado, Rosalía Dacosta‐Aguayo, Irene Navalpotro‐Gómez, Belén Gago, Ana Gorostidi, Haritz Jiménez‐Urbieta, Ana Quiroga‐Varela, Javier Ruiz‐Martínez, Alberto Bergareche, María C. Rodríguez‐Oroz
    Movement Disorders.2018; 33(11): 1809.     CrossRef
  • Extracellular Vesicles as a Source of Urological Biomarkers: Lessons Learned From Advances and Challenges in Clinical Applications to Major Diseases
    Ji-Young Choi, Sujin Kim, Hyo-Bum Kwak, Dong-Ho Park, Jae-Hyoung Park, Jeong-Seon Ryu, Chang-Shin Park, Ju-Hee Kang
    International Neurourology Journal.2017; 21(2): 83.     CrossRef
  • Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease
    Lori N. Eidson, George T. Kannarkat, Christopher J. Barnum, Jianjun Chang, Jaegwon Chung, Chelsea Caspell-Garcia, Peggy Taylor, Brit Mollenhauer, Michael G. Schlossmacher, Larry Ereshefsky, Mark Yen, Catherine Kopil, Mark Frasier, Kenneth Marek, Vicki S.
    Journal of Neuroinflammation.2017;[Epub]     CrossRef
  • Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias
    Julie A Fields
    Archives of Clinical Neuropsychology.2017; 32(7): 786.     CrossRef
Article image
Mechanism of Anti-α-Synuclein Immunotherapy
Jun Sung Lee, Seung-Jae Lee
J Mov Disord. 2016;9(1):14-19.   Published online January 25, 2016
DOI: https://doi.org/10.14802/jmd.15059
  • 26,613 View
  • 350 Download
  • 37 Web of Science
  • 37 Crossref
AbstractAbstract PDF
Immunization therapy targeting α-synuclein has emerged as a promising approach for Parkinson’s disease and perhaps for other synucleinopathies. Several antibodies have shown therapeutic effects in mouse models of synucleinopathies and have alleviated the pathological and behavioral phenotypes of these mice. The mechanisms through which the immunization therapy works were initially puzzling, especially given that α-synuclein is a typical cytosolic protein. Recent studies, however, suggested that extracellular α-synuclein is an important pathogenic entity, and hence, a target for immunotherapy. Here, we review the literature describing immunization therapy for synucleinopathies in mouse models and provide current thoughts on the potential mechanisms underlying the therapeutic effects of α-synuclein immunotherapy.

Citations

Citations to this article as recorded by  
  • Aggregation-Induced Emission Luminogens: A New Possibility for Efficient Visualization of RNA in Plants
    Zheng-Chao Yang, Li-Xiang Zhao, Yu-Qi Sang, Xin Huang, Xuan-Chen Lin, Zhi-Ming Yu
    Plants.2024; 13(5): 743.     CrossRef
  • Oxidative Stress and Dopaminergic Metabolism: A Major PD Pathogenic Mechanism and Basis of Potential Antioxidant Therapies
    Aamir Rasool, Robina Manzoor, Kaleem Ullah, Ramsha Afzal, Asad Ul-Haq, Hadia Imran, Imdad Kaleem, Tanveer Akhtar, Anum Farrukh, Sahir Hameed, Shahid Bashir
    CNS & Neurological Disorders - Drug Targets.2024; 23(7): 852.     CrossRef
  • Effectiveness of Flavonoid-Rich Diet in Alleviating Symptoms of Neurodegenerative Diseases
    Aneta Szulc, Karolina Wiśniewska, Magdalena Żabińska, Lidia Gaffke, Maria Szota, Zuzanna Olendzka, Grzegorz Węgrzyn, Karolina Pierzynowska
    Foods.2024; 13(12): 1931.     CrossRef
  • Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut
    Jacqui T. Nimmo, Harry Smith, Chang Yi Wang, Jessica L. Teeling, James A. R. Nicoll, Ajay Verma, Jean-Cosme Dodart, Zhi Liu, Feng Lin, Roxana O. Carare
    Acta Neuropathologica.2022; 143(1): 55.     CrossRef
  • Autophagy-Related Pathways in Vesicular Unconventional Protein Secretion
    Shin Hye Noh, Ye Jin Kim, Min Goo Lee
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson’s Disease
    Irene Sanchez-Mirasierra, Saurav Ghimire, Sergio Hernandez-Diaz, Sandra-Fausia Soukup
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant
    Rachel Rose, Emma Mitchell, Piet Van Der Graaf, Daisuke Takaichi, Jun Hosogi, Hugo Geerts
    Journal of Pharmacokinetics and Pharmacodynamics.2022; 49(6): 593.     CrossRef
  • Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases
    Falguni Baidya, Mariya Bohra, Aishika Datta, Deepaneeta Sarmah, Birva Shah, Priya Jagtap, Swapnil Raut, Ankan Sarkar, Upasna Singh, Kiran Kalia, Anupom Borah, Xin Wang, Kunjan R. Dave, Dileep R. Yavagal, Pallab Bhattacharya
    Immunology.2021; 162(2): 160.     CrossRef
  • Electrogastrography for diagnosis of early-stage Parkinson's disease
    Nobuyuki Araki, Yoshitaka Yamanaka, Anupama Poudel, Yoshikatsu Fujinuma, Akira Katagiri, Satoshi Kuwabara, Masato Asahina
    Parkinsonism & Related Disorders.2021; 86: 61.     CrossRef
  • Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity
    Simona S. Ghanem, Hend S. Fayed, Qi Zhu, Jia-Hong Lu, Nishant N. Vaikath, Janarthanan Ponraj, Said Mansour, Omar M. A. El-Agnaf
    Molecules.2021; 26(12): 3736.     CrossRef
  • Tat-p27 Ameliorates Neuronal Damage Reducing α-Synuclein and Inflammatory Responses in Motor Neurons After Spinal Cord Ischemia
    Woosuk Kim, Hyun Jung Kwon, Hyo Young Jung, Kyu Ri Hahn, Seung Myung Moon, Yeo Sung Yoon, In Koo Hwang, Soo Young Choi, Dae Won Kim
    Neurochemical Research.2021; 46(12): 3123.     CrossRef
  • Immunotherapies for Parkinson’s Disease: Progression of Clinical Development
    Jet Shee Teng, Yin Yin Ooi, Soi Moi Chye, Anna Pick Kiong Ling, Rhun Yian Koh
    CNS & Neurological Disorders - Drug Targets.2021; 20(9): 802.     CrossRef
  • Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection
    Sheila K. Pirooznia, Liana S. Rosenthal, Valina L. Dawson, Ted M. Dawson, Eric Barker
    Pharmacological Reviews.2021; 73(4): 1204.     CrossRef
  • Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?
    Khalil Mallah, Christine Couch, Davis M. Borucki, Amer Toutonji, Mohammed Alshareef, Stephen Tomlinson
    Frontiers in Immunology.2020;[Epub]     CrossRef
  • Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance
    Miguel Lemos, Serena Venezia, Violetta Refolo, Antonio Heras-Garvin, Sabine Schmidhuber, Armin Giese, Andrei Leonov, Sergey Ryazanov, Christian Griesinger, Gergana Galabova, Guenther Staffler, Gregor Karl Wenning, Nadia Stefanova
    Translational Neurodegeneration.2020;[Epub]     CrossRef
  • Insights Into Peptide Inhibition of Alpha-Synuclein Aggregation
    James H. Torpey, Richard M. Meade, Ravina Mistry, Jody M. Mason, Jillian Madine
    Frontiers in Neuroscience.2020;[Epub]     CrossRef
  • Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
    Jacqui T. Nimmo, Ajay Verma, Jean-Cosme Dodart, Chang Yi Wang, Jimmy Savistchenko, Ronald Melki, Roxana O. Carare, James A. R. Nicoll
    Alzheimer's Research & Therapy.2020;[Epub]     CrossRef
  • Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives
    Khosro Jamebozorgi, Eskandar Taghizadeh, Daryoush Rostami, Hosein Pormasoumi, George E. Barreto, Seyed Mohammad Gheibi Hayat, Amirhossein Sahebkar
    Molecular Neurobiology.2019; 56(7): 4799.     CrossRef
  • The Associations between Immunological Reactivity to the Haptenation of Unconjugated Bisphenol A to Albumin and Protein Disulfide Isomerase with Alpha-Synuclein Antibodies
    Datis Kharrazian, Martha Herbert, Aristo Vojdani
    Toxics.2019; 7(2): 26.     CrossRef
  • Effects of single and combined immunotherapy approach targeting amyloid β protein and α‐synuclein in a dementia with Lewy bodies–like model
    Markus Mandler, Edward Rockenstein, Cassia Overk, Michael Mante, Jazmin Florio, Anthony Adame, Changyoun Kim, Radmila Santic, Achim Schneeberger, Frank Mattner, Sabine Schmidhuber, Gergana Galabova, Brian Spencer, Eliezer Masliah, Robert A. Rissman
    Alzheimer's & Dementia.2019; 15(9): 1133.     CrossRef
  • Translational therapies for multiple system atrophy: Bottlenecks and future directions
    Nadia Stefanova
    Autonomic Neuroscience.2018; 211: 7.     CrossRef
  • Integrin CD11b mediates α-synuclein-induced activation of NADPH oxidase through a Rho-dependent pathway
    Liyan Hou, Xiuqi Bao, Caixia Zang, Hanyu Yang, Fuqiang Sun, Yuning Che, Xuefei Wu, Shao Li, Dan Zhang, Qingshan Wang
    Redox Biology.2018; 14: 600.     CrossRef
  • Serum titers of autoantibodies against α-synuclein and tau in child- and adulthood
    Isabell Kuhn, Tobias Rogosch, Theresa I. Schindler, Björn Tackenberg, Michael Zemlin, Rolf F. Maier, Richard Dodel, Yannick Kronimus
    Journal of Neuroimmunology.2018; 315: 33.     CrossRef
  • Beneficial Effects of Flavonoids Against Parkinson's Disease
    Un Ju Jung, Sang Ryong Kim
    Journal of Medicinal Food.2018; 21(5): 421.     CrossRef
  • Unconventional protein secretion – new insights into the pathogenesis and therapeutic targets of human diseases
    Jiyoon Kim, Heon Yung Gee, Min Goo Lee
    Journal of Cell Science.2018;[Epub]     CrossRef
  • Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy
    Martin Kallab, Marcos Herrera-Vaquero, Malin Johannesson, Fredrik Eriksson, Jessica Sigvardson, Werner Poewe, Gregor K. Wenning, Eva Nordström, Nadia Stefanova
    Frontiers in Neuroscience.2018;[Epub]     CrossRef
  • Gene therapy for neurological disorders: progress and prospects
    Benjamin E. Deverman, Bernard M. Ravina, Krystof S. Bankiewicz, Steven M. Paul, Dinah W. Y. Sah
    Nature Reviews Drug Discovery.2018; 17(9): 641.     CrossRef
  • Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies
    Edward Rockenstein, Gary Ostroff, Fusun Dikengil, Florentina Rus, Michael Mante, Jazmin Florio, Anthony Adame, Ivy Trinh, Changyoun Kim, Cassia Overk, Eliezer Masliah, Robert A. Rissman
    The Journal of Neuroscience.2018; 38(4): 1000.     CrossRef
  • Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects
    Julianna J. Tomlinson, Bojan Shutinoski, Li Dong, Fanyi Meng, Dina Elleithy, Nathalie A. Lengacher, Angela P. Nguyen, Greg O. Cron, Qiubo Jiang, Erik D. Roberson, Robert L. Nussbaum, Nour K. Majbour, Omar M. El-Agnaf, Steffany A. Bennett, Diane C. Lagace,
    Journal of Neural Transmission.2017; 124(6): 721.     CrossRef
  • Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson’s Disease
    Xiaoli Si, Jiali Pu, Baorong Zhang
    Journal of Movement Disorders.2017; 10(2): 69.     CrossRef
  • Membrane Trafficking Illuminates a Path to Parkinson’s Disease
    Takafumi Hasegawa, Naoto Sugeno, Akio Kikuchi, Toru Baba, Masashi Aoki
    The Tohoku Journal of Experimental Medicine.2017; 242(1): 63.     CrossRef
  • Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
    J. Teister, F. Anders, S. Beck, S. Funke, H. von Pein, V. Prokosch, N. Pfeiffer, F. Grus
    Scientific Reports.2017;[Epub]     CrossRef
  • Impact of aging immune system on neurodegeneration and potential immunotherapies
    Zhanfeng Liang, Yang Zhao, Linhui Ruan, Linnan Zhu, Kunlin Jin, Qichuan Zhuge, Dong-Ming Su, Yong Zhao
    Progress in Neurobiology.2017; 157: 2.     CrossRef
  • A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies
    Jess-Karan S. Dhillon, Cara Riffe, Brenda D. Moore, Yong Ran, Paramita Chakrabarty, Todd E. Golde, Benoit I. Giasson, Stephan N. Witt
    PLOS ONE.2017; 12(9): e0184731.     CrossRef
  • Vaccination strategies in tauopathies and synucleinopathies
    Anne K. Braczynski, Jörg B. Schulz, Jan‐Philipp Bach
    Journal of Neurochemistry.2017; 143(5): 467.     CrossRef
  • Missions of <italic>Journal of Movement Disorders</italic>
    Yun Joong Kim
    Journal of Movement Disorders.2016; 9(1): 1.     CrossRef
  • How strong is the evidence that Parkinson's disease is a prion disorder?
    Patrik Brundin, Jiyan Ma, Jeffrey H. Kordower
    Current Opinion in Neurology.2016; 29(4): 459.     CrossRef

JMD : Journal of Movement Disorders Twitter
Close layer
TOP